Key facts
- This page summarizes Martin Doran's Form 3 filing for Vaxxinity, Inc..
- 0 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 10 Nov 2021, 15:58.
Martin Doran - 10 Nov 2021 Form 3 Insider Report for Vaxxinity, Inc.
- Reporting relationship
- Officer
- Issuer ticker
- N/A
- Reported as of
- 10 Nov 2021
- Net transaction value
- $0
- Reporting owner signature
- /s/ Rene Paula, attorney-in-fact for Martin Doran
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Martin Doran filed Form 3 for Vaxxinity, Inc. on 10 Nov 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
VAXX
holding
Class A common stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 22,688
- Date
- 10 Nov 2021
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
VAXX
holding
Derivative
Stock option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 10 Nov 2021
- Ownership
- Direct
- Underlying class
- Class A common stock
- Underlying amount
- 9,406
- Exercise price
- $0.2841
- Footnotes
- F1
VAXX
holding
Derivative
Stock option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 10 Nov 2021
- Ownership
- Direct
- Underlying class
- Class A common stock
- Underlying amount
- 10,560
- Exercise price
- $0.5681
- Footnotes
- F2
VAXX
holding
Derivative
Stock option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 10 Nov 2021
- Ownership
- Direct
- Underlying class
- Class A common stock
- Underlying amount
- 42,244
- Exercise price
- $4.12
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Represents 9,406 time-vesting options. These options are subject to a four-year time-based vesting schedule, with 25% having vested on 12/28/2019 and the remainder vesting in equal installments each month during the remainder of the vesting period.
Footnote F2
Represents 10,560 time vesting options. These options are subject to a four-year time-based vesting schedule, with 25% having vested on 7/1/2021 and the remainder vesting in equal installments each month during the remainder of the vesting period.
Footnote F3
Represents 42,244 time-vesting options. These options are subject to a four-year time-based vesting schedule, with 25% vesting on 1/26/2022 and the remainder vesting in equal installments each month during the remainder of the vesting period.
SEC remarks
Interim Chief Financial Officer, Treasurer and Principal Accounting Officer Exhibit 24 - Power of Attorney